Long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: Results from pooled phase 2b/3 studies

被引：0
|
作者：
Mease, P. J. [1 ,2 ]
Poddubnyy, D. [3 ]
Orbai, A. M. [4 ]
Warren, R. B. [5 ,6 ]
Fleurinck, C. [7 ]
Bajracharya, R. [8 ]
Ink, B. [8 ]
Massow, U. [9 ]
Shende, V [8 ]
Shepherd-Smith, J. [8 ]
Peterson, L. [10 ]
White, K. [8 ]
Landewe, R. [11 ]
Gensler, L. S. [12 ]
机构：
[1] Univ Washington, Swedish Med Ctr, Seattle, WA 98195 USA
[2] Univ Washington, Prov St Joseph Hlth, Seattle, WA 98195 USA
[3] Charite Univ Med Berlin, Dept Gastroenterol Infect Dis & Rheumatol, Berlin, Germany
[4] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD USA
[5] Northern Care Alliance NHS Fdn Trust, Dermatol Ctr, Manchester, Lancs, England
[6] Univ Manchester, NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[7] UCB Pharma, Brussels, Belgium
[8] UCB Pharma, Slough, Berks, England
[9] UCB Pharma, Monheim, Germany
[10] UCB Pharma, Morrisville, NY USA
[11] Amsterdam & Zuyderland MC, Amsterdam Rheumatol & Clin Immunol Ctr, Heerlen, Netherlands
[12] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
SWISS MEDICAL WEEKLY | 2024年 / 154卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IP 7
引用
收藏
页码：35S / 35S
页数：1
相关论文
共 50 条
  • [41] Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
    Proft, Fabian
    Van der Heijde, Desiree
    Schwartzman, Sergio
    Ermann, Joerg
    Marten, Alexander
    Massow, Ute
    Stojan, George
    Taieb, Vanessa
    Voiniciuc, Diana
    Van Tubergen, Astrid
    Compan, Victoria Navarro
    Baraliakos, Xenofon
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1221 - 1223
  • [42] Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
    Baraliakos, Xenofon
    Ranza, Roberto
    Ostor, Andrew
    Ciccia, Francesco
    Coates, Laura C.
    Rednic, Simona
    Walsh, Jessica A.
    Douglas, Kevin
    Gao, Tianming
    Kato, Koji
    Song, In-Ho
    Ganz, Fabiana
    Deodhar, Atul
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [43] Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
    Xenofon Baraliakos
    Roberto Ranza
    Andrew Östör
    Francesco Ciccia
    Laura C. Coates
    Simona Rednic
    Jessica A. Walsh
    Kevin Douglas
    Tianming Gao
    Koji Kato
    In-Ho Song
    Fabiana Ganz
    Atul Deodhar
    Arthritis Research & Therapy, 25
  • [44] Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials
    Curtis, Jeffrey R.
    Mariette, Xavier
    Gaujoux-Viala, Cecile
    Blauvelt, Andrew
    Kvien, Tore K.
    Sandborn, William J.
    Winthrop, Kevin
    de Longueville, Marc
    Huybrechs, Ivo
    Bykerk, Vivian P.
    RMD OPEN, 2019, 5 (01):
  • [45] LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS
    Burmester, G. R.
    Stigler, J.
    Rubbert-Roth, A.
    Tanaka, Y.
    Azevedo, V. F.
    Coombs, D.
    Mccaskill, R.
    Lippe, R.
    Wung, P.
    Gensler, L. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 607 - 608
  • [46] Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
    Baraliakos, Xenofon
    Deodhar, Atul
    Dougados, Maxime
    Oortgiesen, Marga
    de Peyrecave, Natasha
    Bauer, Martin
    Vaux, Thomas
    Fleurinck, Carmen
    van der Heijde, Desiree
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [47] LONG-TERM SAFETY AND TOLERABILITY OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: A PHASE 3, RANDOMIZED, CONTROLLED TRIAL
    Adebajo, A.
    Wells, A.
    Edwards, C.
    Kivitz, A.
    Bird, P.
    Shah, K.
    Hu, C.
    Stevens, R.
    Aelion, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 730 - 730
  • [48] BIMEKIZUMAB REDUCED PSORIATIC ARTHRITIS IMPACT IN PATIENTS WITH PSORIASIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Gossec, Laure
    Gladman, Dafna D.
    Gisondi, Paolo
    de Wit, Maarten
    Ogdie, Alexis
    Ink, Barbara
    Taieb, Vanessa
    Lambert, Jeremy
    Coates, Laura C.
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [49] Long-Term Safety of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses From Phase 2 and 3 Studies
    Bhupathi, Vasudev
    Yu, Bei
    Graham, Christine
    DiPetrillo, Lauren
    Yin, Jiani
    Memisoglu, Asli
    McDonnell, David
    BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S334 - S335
  • [50] Bimekizumab reduced MRI inflammatory lesions in patients with axial spondyloarthritis: Week 52 results from the BE MOBILE 1 and 2 phase 3 studies
    Baraliakos, X.
    Navarro-Compan, V.
    Poddubnyy, D.
    Dubreuil, M.
    Bennett, A.
    Jans, L.
    Massow, U.
    Fleurinck, C.
    Vaux, T.
    Ellis, A.
    de Peyrecave, N.
    Mandl, T.
    Maksymowych, W.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 : 71 - 73
12345